Abstract. The formation of amyloid-containing senile plaques and tau-rich neurofibrillary tangles are central events in Alzheimer disease (AD) pathogenesis. Significantly, AB␣C, a major protein phosphatase 2A (PP2A) holoenzyme, specifically binds to and dephosphorylates tau. Deregulation of PP2A results in tau hyperphosphorylation in vivo. Here, we compared the expression levels and distribution of PP2A subunits in various brain regions from autopsy cases of AD and aged controls with or without histological evidence of age-related neurofibrillary degeneration. Immunoblotting analyses revealed that there was a significant reduction in the total amounts of AB␣C in AD frontal and temporal cortices that matched the decrease in PP2A activity measured in the same brain homogenates. Immunohistochemical studies showed that neuronal AB␣C expression levels were significantly and selectively decreased in AD-affected regions and in tangle-bearing neurons, but not in AD cerebellum and in non-AD dementias. Reduced neuronal AB␣C immunoreactivity closely correlated with tangle load, but not plaque burden, suggesting that AB␣C dysfunction contributes to AD tau pathology. Glial cells within senile plaques were also positive for AB␣C. Increased glial PP2A immunoreactivity was observed in both AD and non-AD cases and may play a role in the brain's response to general inflammatory processes and amyloidogenesis.
INTRODUCTION
Central neuropathological features of Alzheimer disease (AD) are the accumulation of numerous senile plaques (SPs) and neurofibrillary tangles (NFTs) in the hippocampus and neocortex of the affected brain (1) . Large deposits of ␤-amyloid are a hallmark of SPs. Both NFTs and the peripheral neurites found in neuritic-type SPs consist (at the ultrastructural level) of aggregates of paired helical filaments (PHFs) composed of hyperphosphorylated tau molecules. Because highly phosphorylated forms of tau proteins accumulate in AD, it has been suggested that there is an imbalance between the activities of tau-directed kinases and phosphatases in AD (2) . We and others have demonstrated that the serine/threonine protein phosphatase 2A (PP2A) is a major tau phosphatase (3) (4) (5) . Injection of okadaic acid, a selective inhibitor of PP1 and PP2A enzymes, causes tau hyperphosphorylation, amyloid deposition, neurodegeneration, and memory impairment in rat (6) (7) (8) . Indeed, specific inhibition of PP2A alone is sufficient to induce PHF-like tau hyperphosphorylation in cultured cells (4) and in vivo (9) .
A large family of enzymes is hidden under the term ''PP2A,'' which together account for a predominant portion of the total brain phosphatase activity. PP2A holoenzymes are believed to be heterotrimers in vivo (10) , resulting from formation of a complex between scaffolding ''A,'' catalytic ''C,'' and regulatory ''B'' subunits. In mammals, only 2 closely related isoforms (␣ and ␤) of the A and C subunits have been identified, with A␣ and C␣ being the most abundant. In contrast, several distinct multigene families of regulatory subunits termed B (B55 or PR55), BЈ (B56 or PR61), BЉ (PR48, PR59, PR72/ 130), and Bٞ (PR93/PR110) have been uncovered in recent years (11) . Multiple isoforms (␣, ␤, ␥, ␦, . . . ) and splice variants for each family have been identified, thereby generating a great variety of possible PP2A holoenzymes. It is now well recognized that the regulatory subunits are responsible in part for PP2A targeting and functional specificity (11) . For instance, PP2A binds to and dephosphorylates tau in an isoform specific manner (4) . Studies in rat and mouse have shown that specific B subunits are developmentally regulated and display a differential tissue-specific, cellular and subcellular localization (12) (13) (14) . Although the distribution of the C subunit has been investigated by immunohistochemistry in rat brain (15) and human hippocampus (16) , to date, the discrete distribution of specific PP2A subunits remains to be thoroughly examined across a range of human brain regions.
Significantly, overall PP2A activity is diminished in AD brain (17) . One likely explanation for this decrease could be the downregulation of one or more PP2A isoforms. Interestingly, recent microarray analyses have revealed that the expression of the C subunit gene decreases Twenty-four control cases with (ARND) or without (control) evidence of age-related neurofibrillary degeneration and 24 AD cases (AD) with comparable postmortem interval (PMI) values were assayed for PP2A activity and analyzed for PP2A subunit expression by Western blotting. The cases analyzed by immunohistochemistry for PP2A subunit distribution were a representative subset (5 control, 5 ARND, and 12 AD) of those cases. All AD cases met CERAD neuropathological criteria diagnostic for probable and definite AD. Note that cases with a complete range of NFT and SP density (none, sparse, moderate, or frequent according to CERAD criteria) were analyzed in all of our studies. Five non-AD cases comprising vascular dementia (VD), diffuse Lewy body disease (DLBD), and frontotemporal dementia with ubiquitinated inclusions (FTD-Ub) were analyzed only by immunohistochemistry due to the lack of availability of frozen tissue.
in mice hippocampus as a result of aging (18) and is downregulated in early AD as well (19) . A significant loss of the C␣, B55␥, and PR61 subunit mRNA in the AD hippocampus has been described (20) . Although together these findings point to a likely deregulation of PP2A in AD, it is not known whether the protein expression levels or distribution of a specific PP2A holoenzyme are altered in AD.
We have previously shown that AB␣C is a major tauassociated PP2A holoenzyme (4) . The purpose of the present investigation was to provide the first comparative study of the distribution of AB␣C in a large number of cases from control, AD, and non-AD cases. Combined PP2A activity assays, immunohistochemical, and Western blot analyses of brain tissue were used to test the hypotheses that altered distribution of AB␣C contributes to the loss of PP2A activity and correlates with tangle load in AD-affected brain regions.
MATERIALS AND METHODS

Brain Samples
All brain tissue was obtained through the Alzheimer Disease Center (ADC) Brain Bank at UT Southwestern. AD and other demented cases were derived from patients who were evaluated antemortem by the ADC Clinical Core. Control tissue was obtained from 8 subjects who had been evaluated antemortem by the ADC Clinical Core and found to be free of cognitive impairment. Tissue from 16 additional controls was obtained from subjects autopsied at the Dallas County Medical Examiner's Office or at the UT Southwestern Willed Body program, who died of non-neurological causes and had either no neuropathological abnormalities (6 cases) or only limited neurofibrillary changes (10 cases) at autopsy. Detailed clinical records regarding cognitive status were not available for the latter 10 cases. Each brain was processed and diagnosed according to the ADC Neuropathology Core protocol using standard methods. The diagnosis of AD was established according to the CERAD criteria (21, 22) utilizing samples from 16 brain areas fixed in formalin. NFTs and SPs were quantitated on thioflavine-S stained paraffin sections. The general characteristics of the cases studied here are described in Table 1 .
Brain Homogenates
At the time of autopsy, neocortical gray matter was dissected from the middle frontal and superior temporal lobes bilaterally and from the cerebellum, snap-frozen in liquid nitrogen, and stored at Ϫ70ЊC until use. Frozen tissue samples were subsequently thawed on ice, minced, and homogenized at a constant ratio of 1 g tissue/10 ml of buffer (Tris 10 mM, 150 mM NaCl, 2 mM EGTA, 2 mM dithiothreitol, pH 7.4), containing a cocktail of protease inhibitors (Complete mini ; Roche, Indianapolis, IN). Glycerol (10% v/v) was added to the homogenates and aliquots were stored at Ϫ80ЊC. For Western blot analysis and PP2A activity assays, the samples were thawed on ice, briefly sonicated, and centrifuged for 5 min at 14,000 g to remove any remaining insoluble material. The protein concentration of brain homogenates was determined using a Bradford protein assay kit (Bio-Rad, Hercules, CA).
Analysis of PP2A Activity
To remove the free P i that is known to interfere with subsequent phosphatase assays, freshly prepared aliquots of brain homogenates were rapidly passed through pre-equilibrated MicroSpinTM G-25 columns, according to the manufacturer's instructions (Amersham Biosciences, Piscataway, NJ). Aliquots were immediately assayed in triplicate for PP2A activity for 6 min at 30ЊC using the RRREEE(pT)EEE phosphopeptide (BioSynthesis, Inc., Lewisville, TX) as substrate (23) . Dephosphorylation of the peptide was determined by measuring the release of P i using a quantitative malachite-based colorimetric assay (23 1 Using yeast and NIH 3T3 cell lysates expressing HA-tagged B subunits, we found that the polyclonal anti-B ''⌬237'' preferentially reacted with rat B␣ and B␦, and to a lesser extent with human B␤ and rabbit B␥ isoforms. In the same assays, the monoclonal ''2G9'' antibody recognized the rat B␣ and B␦, but reacted extremely weakly with human B␤ and rabbit B␥ subunits (not shown). Based on the comparison of sequences at the 2G9 epitope between distinct species, human B␣ should be recognized equally well by the ''2G9'' antibody as rat B␣, and human B␥ as poorly as rabbit B␥. However, human B␦ looks like human B␤ at this epitope, and should be hardly recognized by the ''2G9'' antibody. Thus, we predict that the recognition preference for the ''2G9'' antibody in human is: B␣ k B␦, B␤ k k B␥. 2 These antibodies were not utilized in our immunohistochemical studies because they were found to cross-react with unidentified proteins during Western blot analysis of total human brain extracts and/or to display excessively low signal/background ratios during immunostaining of human brain tissue.
assayed to ensure the linearity of the dephosphorylation reaction. PP2A activity was defined as the activity that was sensitive to 5 nM okadaic acid (LC Laboratories, Woburn, MA) (24) .
Western Blot Analysis
Equivalent aliquots (ϳ40 l) of brain homogenates were resolved by SDS-PAGE on 10% polyacrylamide gels (Amersham Biosciences) and analyzed by immunoblotting for the presence of PP2A subunits using the antibodies described in Table 2 . Immunoreactive proteins were detected using SuperSignal Chemiluminescence substrates (Pierce, Rockford, IL). Immunoblots were scanned by densitometry and quantitated using Kodak Image software (Eastman Kodak Company, Rochester, NY).
Statistical Analysis
The data are presented as mean value Ϯ SD and were analyzed using the Student t-test. Differences were considered statistically significant with p values Ͻ 0.05.
Immunohistochemistry
Paraffin sections (3 m thick) from normal or diseased human brain cortices were immunostained at room temperature on a BioTek Solutions TechMate TM 1,000 automated immunostainer (Ventana Medical Systems, Tucson, AZ). Buffers, blocking solutions, secondary antibodies, avidin/biotin complex reagents, and chromogen were used as supplied in the Ultra-Streptavidin secondary detection kit for horseradish peroxidase (HRP)/diaminobenzidine (DAB) staining (Signet Laboratories, Inc., Dedham, MA), and the ChemMate TM secondary detection kit for alkaline phosphatase/BT red staining (Ventana Medical Systems). Optimum primary antibody dilutions were predetermined using known positive control tissues. A known positive control section was included in each run to assure proper staining. Sections were deparaffinized in xylene and ethanol, washed, and incubated with 3% H 2 O 2 to inhibit endogenous tissue peroxidase activity. After washing, sections were placed in 200 ml heat-induced epitope retrieval (HIER) buffer (BioPath Laboratories, Inc., Oklahoma City, OK), pH 6. The buffer was brought to a boil, after which 50 ml of deionized water was added. The buffer was again brought to a boil for 5 min, then the slides were allowed to cool in buffer for 20 min, following which they were rinsed thoroughly in deionized water and then buffer. Sections were incubated in blocking serum for 5 to 10 min, then for 25 min with either the first primary antibody diluted in buffer or with buffer alone (negative control). After washing, sections were incubated for 25 min with secondary antibody solution containing biotinylated goat anti-mouse, goat anti-rabbit, or horse anti-goat antibodies. Sections were then incubated for 25 min with HRP-conjugated avidin-biotin complex, washed in buffer, and then incubated with a mixture of DAB and H 2 O 2 in buffer. After washing, sections were incubated for 25 min with either the second primary antibody diluted in buffer or with buffer alone (negative control). (Table 1) . Results are expressed as percent of the relative PP2A activity measured in control cases and are the mean Ϯ SD of triplicate determinations. The average released P i in control cases was ϳ19, 42, and 8 pmol/min/l brain sample from the frontal, temporal, and cerebellar regions, respectively. The average released P i measured in all assays varied between 7 and 10 nmol/min/mg brain extract.
in buffer, sections were incubated for 25 min with biotinylated goat anti-mouse, goat anti-rabbit, or horse anti-goat antibody solution, and for 25 min with alkaline phosphatase-conjugated avidin-biotin complex. Sections were then washed in buffer and incubated with a solution of BT Red, followed by washing in buffer and water. Sections were counterstained with hematoxylin, dehydrated in a graded series of ethanols and xylene, and coverslipped. Sections were photographed on a Nikon Optiphot microscope (Nikon Instruments, Melville, NY). Positive reactions with DAB were identified as dark brown reaction product. Positive reactions with BT red were identified as red reaction product.
RESULTS
PP2A Activity and B Subunit Expression Levels Are Altered in AD-Affected Brain Regions
In this study, we first compared PP2A activity and subunit expression levels in brain homogenates from a series of neuropathologically confirmed autopsy cases of AD (AD) and of aged controls, with histological evidence of age-related neurofibrillary degeneration (ARND) or without such evidence (controls) ( Table 1) . Particular care was taken to select cases with relatively short postmortem interval (PMI) times, since it has been previously demonstrated that the loss of PP2A activity is minimal in autopsied human postmortem tissue under such conditions (17) . Because the neuropathology in AD is characterized by extensive neuronal cell loss in affected areas, we chose to compare PP2A properties in defined brain tissue samples that had been carefully normalized by homogenization at a fixed ratio (tissue weight/buffer volume). Relative to controls, PP2A activity levels were not statistically different in ARND (p ϭ 0.317), but significantly reduced in AD (p Ͻ 0.001) frontal cortex homogenates (Fig. 1) . When analyzing tissue extracts prepared from the corresponding temporal cortex, a region more severely affected by AD pathology, PP2A activity levels were decreased slightly in ARND (p Ͻ 0.001), and maximally in AD (p Ͻ 0.001), compared to control cases. However, no significant differences in PP2A activity levels were found in corresponding brain samples from ARND (p ϭ 0.06) and AD (p ϭ 0.1) cerebellum compared to controls. These results suggest that changes in overall PP2A activity specifically occur in AD-affected, but not unaffected, regions.
To determine whether the regional reduction in PP2A activity correlated with changes in the expression levels of one or more PP2A subunits, aliquots of the same brain homogenates were analyzed by gel electrophoresis followed by Western blotting using a battery of PP2A antibodies, most of which had not been previously characterized in human brain extracts (Table 2 ). Figure 2 shows representative blots of frontal homogenates from 4 AD and 4 control cases revealed with several of these anti-PP2A subunit antibodies. Many antibodies were found to recognize the corresponding antigens, but also noticeably cross-reacted with unknown proteins (e.g. anti-B␣ (14-27), anti-B␤); others gave very poor signal/background ratios. Those were consequently excluded from utilization in subsequent immunohistochemical studies (Table  2) . Indeed, among all the antibodies tested here, only the anti-〈␣, anti-C␣, anti-B ''2G9,'' and anti-B ''⌬237'' antibodies gave a single band and specific signal by immunoblotting of human brain extract. It is known that antibodies raised against the B␣ subunit (e.g. ''2G9'' and ''⌬237'' antibodies) may, to some extent, cross-react with the B␤, B␦, or 〉␥ subunits due to sequence homologies among B subunits. The signal obtained with the ''2G9'' and ''⌬237'' antibodies during Western blotting of human brain extract was completely abolished by pre-incubating Table 1 were analyzed by Western blotting for the presence of PP2A subunits using the various antibodies described in Table 2 . Representative blots are shown for 4 severe AD (lanes 1-4) and 4 aged control (lanes 5-8) cases.
Fig. 3.
Comparative analysis of B␣ subunit expression levels in frontal, temporal, and cerebellar regions from control, ARND, and AD cases. All the cases described in Table 1 that were quantitated for PP2A activity (Fig. 1) were analyzed by Western blotting for B␣ subunit expression levels. The relative amounts of B␣ subunit in the frontal (A), temporal (B) cortices, or cerebellum (C) were estimated by quantitative densitometric analysis of the immunoblots. Results are expressed as percent of the relative B␣ expression levels measured in control cases and are the mean Ϯ SD of determinations performed with the ''2G9'' and ''⌬237'' antibodies. those antibodies with purified B␣ proteins, but not with B␤ subunits (not shown). Together with data from reactivity studies and sequence prediction (Table 2) , these observations suggest that the ''2G9'' and ''⌬237'' antibodies primarily recognized human brain B␣, with the ''2G9'' antibody being the most specific. Interestingly, the total expression levels of the B␣, but not the B␤ and BЈ␣ regulatory subunits were clearly decreased in AD compared to controls. A small reduction in the total amounts of the A and C subunits was also visible in AD cases. Similar expression patterns were obtained during immunoblotting of corresponding temporal brain homogenates (data not shown). Further quantitative densitometric analysis of immunoblots of all 48 cases examined in this study indicated that B␣ subunit expression levels in frontal and temporal cortex homogenates were somewhat lower in ARND (p Ͻ 0.001), and reduced by approximately half in AD cases (p Ͻ 0.001) relative to control cases (Fig. 3) . In contrast, B␣ subunit amounts in the cerebellum were not statistically different in ARND (p ϭ 0.07) and AD (p ϭ 0.06) cases relative to control cases, suggesting that reduced B␣ subunit expression preferentially took place in AD-affected regions.
AB␣C Distribution in Normal Human Brain
Because components from distinct cell populations are present in our brain homogenates and the number of tangle-bearing neurons is on average relatively small compared to the total number of neurons even in the most severely affected brain regions in AD, Western blotting data are not fully informative regarding potential regional losses or cell-type specific changes in PP2A expression levels. Thus, to gain further insights into the discrete brain distribution of PP2A subunits, cortical sections from a subset of the cases analyzed for PP2A activity and expression (Table 1) were also examined by immunohistochemistry. Because of the lack of specific PP2A subunit antibodies (Table 2) , and since B-containing PP2A heterotrimers selectively bind to and dephosphorylate tau (4, 23) , immunohistochemical analyses were exclusively performed with anti-A␣, anti-B ''2G9,'' and anti-C␣ subunits antibodies. Of note, because free A, B, or C subunits are unstable in vivo (10), antibodies directed against B␣ can be utilized to specifically detect corresponding AB␣C hetrotrimers (25) , whereas antibodies raised against the A or C subunits recognize all PP2A holoenzymes. Because of its specificity, we preferentially used the monoclonal ''2G9'' antibody, but similar results were obtained with the polyclonal anti-B ''⌬237'' antibody (data not shown). There was a complete loss of immunoreactivity when sections were incubated with corresponding pre-immune sera, or with antibodies pre-adsorbed with purified B␣ proteins. In contrast, the immunostaining pattern was unaffected when labeling was performed with antibodies pre-adsorbed with purified B␤ subunits, confirming that our anti-B antibodies preferentially recognized the B␣ subunit in human brain. As illustrated in Figure 4 , all PP2A subunit antibodies examined here strongly labeled both the soma and neurites of pyramidal and granular neurons in the frontal and temporal lobes, in agreement with previous comparable studies performed in mouse and rat brain tissue (12, 14) . In addition, immunostaining of endothelial and glial cells was regularly observed with these antibodies throughout the cortex, although its intensity varied depending on the antibody utilized. The abundance and widespread distribution of these PP2A subunits also likely explains the general ''background''-like appearance of the specific staining in these sections, a phenomenon already noted in earlier PP2A immunohistochemical studies performed in rat brain (12) . Thus, the distribution of the B␣ subunit overlapped with those of the A and C subunits in the frontal and temporal cortex. In the cerebellum, however, B␣ subunits were less abundant and their localization restricted to selective cellular populations, unlike the A and C subunits that were broadly distributed in both the granular and molecular layers. Moreover, Purkinje cells were intensely labeled with anti-A␣ and anti-C␣ antibodies, but faintly stained with our anti-B␣ antibodies, as previously reported in mouse (14) , but in contrast to findings reported in rat (12) .
Altered AB␣C Expression Is Associated with the Presence of PHF-Tau Pathology
Next, the distribution of AB␣C was investigated in AD brain. Double labeling with the monoclonal PHF-1 antibody was used to specifically identify pathological PHFtau containing lesions (Fig. 5) . Neurons bearing nascent tangles were positive for the A, B␣, and C subunits (Fig.  5A-C) . However, neurons completely filled with tangle material were hardly, if at all, stained with anti-PP2A subunit antibodies (Fig. 5D-F) . Indeed, there was a mutually exclusive localization of PP2A subunits and PHFtau in severe AD cases with only tangle-free neurons remaining immunoreactive with anti-PP2A subunit antibodies. Noticeably, dystrophic neurites were completely negative for PP2A. There was also a significant overall decrease in total neuronal immunoreactivity in frontal AD sections. The reduction in the general intensity of the immunostaining was especially pronounced with the anti-B ''2G9'' antibody and matched the overall decrease in total B␣ expression levels that we observed in corresponding brain homogenates (Figs. 2, 3A) . However, enhanced glial cell labeling was widely observed with PP2A subunit antibodies. Further comparative examination of ARND cases as well as AD cases with a range of NFT and SP density suggested that the decrease of neuronal B␣ immunoreactivity closely paralleled tangle/dystrophic neurite load in the frontal cortex (Fig. 6) . However, seemingly comparable levels of glial B␣ staining were observed in all the cases, regardless of tangle severity. Similar immunostaining patterns were found in corresponding temporal sections; in contrast, the distribution of the A, B␣, and C subunits was indistinguishable in the cerebellum from control and AD cases (data not shown). Lastly, the distribution of AB␣C was investigated in the hippocampus, a region particularly vulnerable to AD lesions (Fig. 7) . In the hippocampal CA1 region, an area affected especially severely in AD, neuronal AB␣C immunoreactivity was very intense in ARND (Fig.  7A, B ), but extremely weak in severe AD (Fig. 7C, D) cases. The overall reduction in AB␣C immunoreactivity was not as robust in the same sections in the corresponding CA2/CA3 regions (Fig. 7E-H) , which were less affected than the CA1 region in AD. Yet, there was again a striking mutually exclusive neuronal localization of PHF-tau and AB␣C. As observed in the frontal/temporal cortex, only neurons that were not completely filled with tangles were still AB␣C-positive. Together with our previous findings, these results indicate that there is a gradient of regional AB␣C immunoreactivity that is intimately linked to AD lesion severity. Moreover, the progressive loss of AB␣C closely parallels or reflects the formation of pathological tau lesions in discrete neurons.
Reduced Neuronal AB␣C Immunoreactivity Does Not
Correlate with the Presence of Amyloid Plaques
In the next series of experiments, double labeling with anti-␤-amyloid (A␤) antibody was utilized to address the hypothesis that changes in AB␣C expression were also associated with the presence of ␤-amyloid-containing SPs, another key AD neuropathological marker (Fig. 8) .
Representative sections in Figure 8A -D show that pronounced neuronal AB␣C immunoreactivity, indistinguishable from that observed in control cases, was present in the areas immediately surrounding SPs. In fact, comparison of cases with sparse NFTs and concomitant sparse or frequent SP density indicated that there was no apparent correlation between amyloid plaque density per se and qualitative changes in neuronal AB␣C expression levels. However, the overall loss of neuronal AB␣C immunoreactivity was much more prevalent in AD cases with both frequent SPs and NFTs. Significantly, antibodies against AB␣C frequently stained very intensely the activated microglial cells and macrophages that are associated with mature plaques, but not the ␤-amyloid core itself of both diffuse or neuritic SPs (Fig. 8E-H) . Together with our findings shown in Figure 6 , these observations suggest that the selective decrease in neuronal AB␣C expression levels in AD most strictly correlates with tangle load, but not amyloid volume. On the other hand, enhanced expression of AB␣C in activated glial cells does not correlate with tangle load, but may be an important contributing factor to amyloidogenesis.
Neuronal AB␣C Expression Is Not Altered in Non-AD Dementias without Tau Pathology
Lastly, to determine whether changes in AB␣C expression did not result from neurodegenerative processes present in other common non-AD dementias, we compared by immunohistochemistry PP2A subunit distribution in VD, DLBD, and FTD-Ub cases ( Control cases were double stained in parallel to ensure the consistency of the immunostaining procedures. Of note, the intensity and pattern of PP2A distribution in control cases double labeled with anti-PP2A and PHF-1 antibodies was indistinguishable from that of the same cases single labeled (Fig. 4) with anti-PP2A antibodies (data not shown; but see for instance Fig. 8A-D) .
The soma and neurites of neurons were intensely stained with anti-PP2A subunit antibodies in diseased regions of all these cases, even in areas where decreased neuronal density was present as a result of brain atrophy. Reactive glia staining was also repeatedly seen in these cases; it was especially intense in DLBD cases, but less pronounced in FTD-Ub cases. As expected, no immunoreactivity was observed in these sections with PHF-1 antibody, confirming the absence of tau pathology in these cases. Thus, the decrease of neuronal AB␣C immunoreactivity observed in AD probably does not derive from random or general neurodegenerative events.
DISCUSSION
In the present study, we simultaneously compared for the first time PP2A activity and the expression levels and distribution of human A, B, and C subunits in a large series of brain regions and cases. So far, studies aimed at assessing PP2A distribution and protein expression levels in human control and AD brain tissue had relied exclusively on the utilization of polyclonal anti-C subunit antibodies (16, 27) . In one immunohistochemical study of AD hippocampus, the authors concluded that the expression of the serine/threonine phosphatase PP2B, but not PP2A, was selectively decreased in tangle-bearing neurons (16) . In another study, the levels of the C subunit were quantitated by indirect ELISA in superior temporal cortical grey matter of AD and control brains (27) and failed to demonstrate any downregulation of the levels of PP2A in total AD brain homogenates. There are 2 major problems associated with these studies. First, the polyclonal antibodies used were raised against the carboxyterminus of the C subunit. It has been shown that most of PP2A C subunit is methylated in mammalian cells on the Leu309 site in the conserved C-terminal sequence, which hinders recognition by antibodies raised against the carboxy-terminal sequence of this subunit (28) . Secondly, because the C subunit is common to all PP2A isoforms, the exclusive utilization of anti-C antibodies does not allow one to single out whether a selective isoform of PP2A is deregulated in AD. Since the PP2A family comprises dozens of isoforms with clearly distinct functional specificities and the regulation of tau by PP2A is isoform-specific (4), the issue of defining which PP2A The immunostaining pattern in this ARND case is similar to that observed in control cases (Fig. 4B) . B: AD case (sparse NFTs; frequent SPs). Neurons are still highly immunoreactive to the ''2G9'' antibody. C: AD case (moderate NFTs; frequent SPs). Note the reduced neuronal PP2A immunoreactivity. D: Severe AD case (frequent NFTs; frequent SPs). Note the faint or absent overall neuronal PP2A immunoreactivity. In all cases (A-D), significant PP2A immunoreactivity can be observed in glial cells (arrows). Similar results were observed in corresponding temporal sections of the same cases (not shown).
holoenzyme might be deregulated or redistributed in AD is of paramount importance. Unfortunately, due to the relative identity of some regulatory subunits, many of the so-called isoform-specific antibodies that have been generated to date cross-react with other PP2A isoforms. The lack of specific antibodies has considerably hampered the study of the distribution of endogenous PP2A regulatory subunits in mammalian tissue and was a hurdle for the present study as well. For instance, the commercially available anti-B␣ and anti-B␤ antibodies from Calbiochem have been reported to be specific for the B␣ and B␤ isoforms of PP2A, respectively, and have been used in previous immunoblotting and immunohistochemical studies performed in mouse and rat (12, 14) . However, in our hands, these antibodies, as well as other commercially available anti-B subunit antibodies (Table 1) , either recognized weakly the corresponding B subunit isoform or cross-reacted with other proteins in human brain tissue. Thus, after careful characterization, we chose to use the anti-B ''2G9'' for our studies because it preferentially recognized the B␣ subunit in human brain. Yet, we cannot exclude the possibility that it cross-reacted with other or yet unknown regulatory subunit isoforms that could not be tested here.
Because of the lack of PP2A isoform-specific antibodies, recent mRNA analyses of control and AD brain tissue were performed using isoform-specific probes, which led to the conclusions that there is a considerable loss of the C␣, B␥, and PR61␥, but not B␣ subunit mRNAs in AD (20) . In contrast to those studies, we report for the first time that there is a significant and selective decrease of B␣ subunit expression in AD. Although quantitative differences are difficult to determine by immunohistochemistry, there were some irrefutable parallels in the reduction of B␣ expression levels detected by immunoblotting and the loss of neuronal immunoreactivity observed in ADaffected regions and tangle-bearing neurons. Discrepancies between our present findings and those of Vogelsberg et al could be explained by the fact that, in contrast to our studies (Table 1) , mRNA analyses were carried out on a very small sample of cases (4 AD cases and 2 controls) with very long PMI times (9-26 hours). Accurate mRNA quantification and statistically significant data are arguably quite difficult to obtain under such experimental conditions. Alternatively, significant regulation of B␣ subunit translation and/or stability at the protein level may occur. Indeed, free B␣ subunits are known to be downregulated (10) . Other PP2A regulatory subunits such as B␥ and PR61␥, which were not studied here due to the lack of availability of specific antibodies, could also be decreased in AD.
In agreement with the loss of C␣ mRNA observed in AD hippocampal neurons (20) , our immunohistochemical analyses of AD-affected brain regions revealed that there was also a significant decrease of C␣ as well as A␣ subunit expression in AD-affected neurons. Yet, the overall loss of neuronal immunoreactivity in AD was more pronounced when labeling was performed with anti-B, rather than with anti-A or anti-C antibodies. In contrast to the results from our immunohistochemical studies, immunoblotting data revealed that the total expression levels of the A and C subunits were only marginally reduced in AD frontal/temporal brain homogenates, relative to controls. Earlier quantitative ELISA studies have failed to demonstrate any significant changes in the amounts of C subunit in temporal brain homogenates from AD cases compared to controls (27) . The inability to detect significant changes in A and C subunit expression in total brain homogenates can likely be explained by the fact that the A and C subunits are common to all PP2A isoforms and are widely expressed in all brain cell types.
Previous immunohistochemical analyses of AD hippocampus performed in 5 cases of mild severity have indicated that the C subunit was localized in neurons with all stages of NFTs and with amyloid plaques (29) . Here, we show that PP2A subunit antibodies primarily stained the microglial cells surrounding SPs, but not the ␤-amyloid core of the plaques per se. Moreover, neurons with nascent tangles, but not neurons completely filled with tangles, or dystrophic neurites, were positive for AB␣C. Although immunohistochemistry is by and large qualitative, there was a clear indication that the overall reduction in neuronal AB␣C immunoreactivity correlated with tangle load and AD severity. Decreased AB␣C expression in tangle-bearing neurons suggests that either the presence of PHFs in a neuron decreases its capacity to synthesize specific gene products like PP2A subunits, or that deregulation of AB␣C is a contributing cause to AD pathogenesis.
In contrast to earlier findings from rat brain studies (12) , but in agreement with results from previous studies done in mouse brain (14) and from mRNA analyses performed in human brain (20) , we found that anti-B␣ antibodies strongly labeled glial cells in control and diseased human brain cortex. Because glial AB␣C immunoreactivity appeared to be increased in AD relative to controls, the decrease of PP2A subunit expression per neuron may be higher than predicted from immunoblotting studies. In addition, Pei et al have reported that PP2A C subunit was localized in microglia in normal hippocampus (16) . C subunit levels measured by ELISA were elevated in the post-synaptosomal compartment of AD temporal cortex (30) and correlated with the levels of hyperphosphorylated tau (27) . Likewise, we found enhanced C subunit immunoreactivity in activated glial cells in AD. However, in our case, it was not specific to AD and did not correlate with the presence of NFTs, since it was also observed in non-tauopathy dementias. Thus, enhanced glial AB␣C immunoreactivity appears to be the result of inflammatory processes commonly triggered in many disorders other than AD.
Recently, it was reported that in hippocampal formation and frontal cortex, tangle and neuron numbers, but not amyloid load, closely reflect the progression of cognitive defects in brain aging and AD (31) . Interestingly, we observed a similar apparent correlation between reduced neuronal AB␣C immunoreactivity and NFT density, but not SP density. Because AB␣C is an essential and major PP2A holoenzyme that critically regulates cytoskeletal functions and signal transduction pathways (11) , an overall decline in its expression is detrimental to neuronal integrity and survival. Importantly, changes in AB␣C expression levels in AD-affected regions not only affect PP2A activity, but also its substrate specificity. Indeed, we have reported that B␣-subunit containing PP2A holoenzymes preferentially interact with and dephosphorylate tau (4) and that PHF-like phosphorylated tau has decreased binding affinity for AB␣C (32) . Thus, our immunohistochemical data strongly support the hypothesis that altered interactions between AB␣C and PHF-tau (as a result of PP2A and/or tau deregulation) could contribute to AD tau pathology by promoting the accumulation of hyperphosphorylated tau species. In addition, (FTD-Ub) ; E, F: Diffuse Lewy body disease (DLBD). Note that the field shown in panel E was chosen to especially highlight the strong axonal and glial PP2A immunoreactivity. In all panels, note the absence of PHF-1-immunoreactive NFTs and preservation of neuronal PP2A immunoreactivity.
our findings suggest that enhanced expression of PP2A in activated glial cells may also be an important contributor to the local immune response in the brain to general insults, as well as to amyloidogenic events in AD (33) . While the downregulation of the C subunit gene/mRNA has been reported during aging (18) and in AD (19, 20) , our findings provide the first evidence for changes in protein expression levels of a major and specific PP2A holoenzyme in AD. Together, these observations reinforce the concept that, in addition to other etiological factors, PP2A dysfunction may be linked to the onset/progression of AD rather than occurring subsequent to more general neurodegenerative events. In any case, the fact that intrinsic deregulation of a predominant brain enzyme like PP2A has the potential to promote or accelerate damaging neurodegenerative processes that predominate in AD cannot be denied. Additional studies will be needed in the future to elucidate the causes of PP2A dysfunction in AD and determine whether it also occurs in non-AD tauopathies.
